Multi-omics integration and functional validation identify thrombospondin-1 as a functionally relevant mediator of doramectin-associated inhibition of glioblastoma migration and invasion.
Aug 2026· International Journal of Biological Macromolecules· pp.
154154
· 0 citations· 56 references
Medicine
TL;DR
RNA sequencing of DRM-treated versus control rat C6 glioma cells identified 3747 differentially expressed genes, including 1660 upregulated and 2087 downregulated genes, with thrombospondin-1 markedly downregulated after DRM treatment, which may contribute to the anti-invasive effects of DRM.
Abstract
Glioblastoma (GBM) exhibits highly infiltrative growth that limits therapeutic efficacy and promotes recurrence. Although doramectin (DRM) has been shown to induce apoptosis and autophagy in GBM cells, its effects on tumor migration and invasion remain unclear. We performed integrative transcriptomic and functional analyses to identify mediators associated with DRM anti-invasive activity. RNA sequencing of DRM-treated versus control rat C6 glioma cells identified 3747 differentially expressed genes, including 1660 upregulated and 2087 downregulated genes, with thrombospondin-1 (THBS1) markedly downregulated after DRM treatment (log2 fold change = -5.9). These genes were mainly associated with extracellular matrix organization, focal adhesion, phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling, and migration-related pathways. Public single-cell, spatial transcriptomic, and pan-cancer analyses provided contextual evidence of heterogeneous expression across tumor cellular and spatial contexts and is associated with tumor-related functional states. Under matched 24 h conditions, 5-20 μM DRM dose-dependently suppressed glioma cell adhesion, wound closure, migration, and invasion, with 20 μM DRM reducing Transwell migration and invasion by approximately 82-93% relative to the corresponding 0 μM control group. THBS1 knockdown reduced migration and invasion, whereas THBS1 overexpression partially restored migration and invasion under DRM treatment; these effects were accompanied by changes in matrix metalloproteinase 2 and matrix metalloproteinase 9 (MMP2 and MMP9) expression and focal adhesion kinase (FAK)/Akt phosphorylation. Collectively, THBS1 is functionally associated with GBM invasive phenotypes and may contribute to the anti-invasive effects of DRM, with extracellular matrix remodeling and FAK/Akt-related phosphorylation changes representing plausible associated processes.
Findings identify NTMT1 as a candidate regulatory node associated with MYC activation and downstream HLA-A suppression, warranting further mechanistic and in-vivo investigation, and highlighting NTMT1 as a promising candidate for future therapeutic investigation.
Jin-Ling Zhang, Chen Chen, Huibin Song et al.· Frontiers in Immunology· 0 citations
PPFIA1 emerges as a pan-cancer biomarker with prognostic significance and shows an oncogenic role in PAAD, potentially associating with EMT-related malignant phenotypes and warrants further investigation as a candidate biomarker and potential functional target for precision oncology.
Shu Li, Hailin Jiang, Xiaojia Li et al.· Frontiers in Oncology· 0 citations
A previously unrecognized NCOA5–ZCCHC3/FGF22 axis that drives LUAD progression is identified and new mechanistic insight is provided into the role of NCOA5 in LUAD biology.
Yiran Yu, Wen Jin, Erdun Chaogetu et al.· Cell Death & Disease· 0 citations
FZD5 is a TAM-enriched marker in glioma tissues and a potential regulator of macrophage-associated immunosuppressive programs, supporting its utility as a prognostic biomarker and a candidate target for microenvironment-oriented interventions in glioma.
The findings identify DRG1 as a potential prognostic biomarker and therapeutic target in HCC and identify its underlying regulatory mechanisms as a potential strategy to improve lenvatinib response.
A highly distinct aGPCR dysregulation signature characterized by the massive upregulation of ADGRG7 and ADGRF1 is identified within the PAAD microenvironment, highlighting them as promising diagnostic biomarkers and actionable therapeutic targets for overcoming TME-mediated immunosuppression.
A. A. Khan, Sung-Gook Cho· Anticancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.